Skip to main content
. Author manuscript; available in PMC: 2020 Apr 12.
Published in final edited form as: Psychoneuroendocrinology. 2016 Apr 8;69:150–160. doi: 10.1016/j.psyneuen.2016.04.008

Table 1.

Sample demographics.

Cohort Johns Hopkins Prospective PPD Cohort Prospective Gene Expression PPD Cohort FRAMES cohort

Total 51 61 240
PPD: Antenatal Euthymic 10 1st:15; 3rd: 15 5
PPD: Antenatal Depressed 12 1st:14; 3rd: 18 0
No PPD: Antenatal Euthymic 22 1st:22; 3rd: 28 235
No PPD: Antenatal Depressed 7 0 0
PPD Assessment Prospective Clinical Prospective HDRS, BD1, EPDSa Prospective HDRS
Age 30.68 ±6.32 33 32.7 ± 0.018
1st trimester 9 51 0
2nd trimester 22 0 0
3rd trimester 20 61 0
Postpartum 0 0 240
% Caucasian: African American: Other 30:70:0% 85:15:0% 100:0:0%
Childhood Sexual Abuse 19 NA NA
No Childhood Sexual Abuse 29 NA NA
Procedures
Illumina HM450 beadchip 51 0 0
OXTR Targeted Pyrosequencing 51 0 240
Illumina HumanHT-12 V4.0 expression beadchip 0 61 0
Hormone Analysis 31 0 0
a

Depression diagnoses as reported by Mehta et al. (2014) for the various time points were based on satisfying all of the following criteria: 1st trimester: Hamilton Depression Rating Scale (HDRS)>14, Edinburgh Postnatal Depression Scale (EPDS)>12, Beck Depression Inventory (BDI)>15; 3rd Trimester: HDRS>15, EPDS>15, BDI>12; 3 months postpartum: HDRS>14, EPDS>11, BDI>16.